Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Color
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Legal
  • Movers
  • News
  • Reiteration
  • Trading Ideas

What’s Going On With Danish Healthcare Firm Genmab Stock?

By Vandana Singh
January 23, 2:11 PM
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.

GMAB

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Initiation
  • Long Ideas
  • Movers
  • News
  • Short Ideas
  • Top Stories
  • Trading Ideas

Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: ‘Innovation Is Key’

By Priya Nigam
January 23, 1:47 PM
Innovation and digitalization have been in focus among ophthalmology majors.

ALC

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study

By Vandana Singh
January 23, 12:11 PM
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

BMY

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Health Care
  • Large Cap
  • Markets
  • Movers
  • News

Johnson & Johnson’s Clock 12% Q4 Revenue Growth, Cancer and Crohn’s Disease Drugs Account as Largest Sellers

By Vandana Singh
January 23, 10:49 AM
Johnson & Johnson's Q4 2023 performance, with adjusted earnings up 11.7%, sales at $21.4 billion, and key insights into pharmaceutical and MedTech segments.

JNJ

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Bristol Myers Squibb’s Combo Therapy Shows Sustained Benefits Over Pfizer’s Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup

By Vandana Singh
January 23, 9:23 AM
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight years.

BMY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment

By Vandana Singh
January 23, 9:19 AM
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies. 

AZN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • Movers
  • News
  • Trading Ideas

French Drugmaker Sanofi Agrees To Buy Inhibrx’s Candidate For Rare Genetic Indication, For About $2.2B

By Vandana Singh
January 23, 9:00 AM
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.

INBX

Read More
2 minute read
  • Health Care
  • News
  • Tech
  • Top Stories

Apple Vision Pro For Healthcare? Surgeon Thinks It Can Give ‘Superpowers’ To Doctors: ‘I Am Excited’

By Rounak Jain
January 23, 4:37 AM
Dr. Rafael Grossmann, the first surgeon to introduce Google Glass to the operating room, is anticipating the launch of Apple Vision Pro.

AAPL

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Downgrades
  • Equities
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades

By Vandana Singh
January 22, 3:37 PM
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.

ACRS

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • News
  • Reiteration
  • Trading Ideas

Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study

By Vandana Singh
January 22, 3:35 PM
Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission.

IONS

Posts pagination

Previous 1 … 73 74 75 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service